Tofacitinib for the treatment of lichen planopilaris: A case series.
증례연속
4/5 보강
TL;DR
Treatment with oral tofacitinib either as monotherapy or adjunctive therapy can lead to measurable improvement in recalcitrant LPP.
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
10 patients with recalcitrant LPP who were treated with oral tofacitinib.
I · Intervention 중재 / 시술
oral tofacitinib
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
No other adverse effects were reported. Treatment with oral tofacitinib either as monotherapy or adjunctive therapy can lead to measurable improvement in recalcitrant LPP.
📑 코퍼스 인용 관계
· 인용됨 14
📑 인용한 논문 (6) ▾
- Frontal Fibrosing Alopecia: A Comprehensive Review with Recent Updates. Indian journal of dermatology · 2025
- Off-Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Cu… Experimental dermatology · 2025
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a nar… Archives of dermatological research · 2025
- The Frontal Fibrosing Alopecia Treatment Dilemma. Journal of clinical medicine · 2024
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatrici… PloS one · 2024
- JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring a… EMBO molecular medicine · 2024
연도별 인용 (2013–2026) · 합계 126
OpenAlex 토픽 ·
Hair Growth and Disorders
Dermatology and Skin Diseases
Autoimmune Bullous Skin Diseases
Treatment with oral tofacitinib either as monotherapy or adjunctive therapy can lead to measurable improvement in recalcitrant LPP.
APA
Christine C. Yang, Trisha Khanna, et al. (2018). Tofacitinib for the treatment of lichen planopilaris: A case series.. Dermatologic therapy, 31(6), e12656. https://doi.org/10.1111/dth.12656
MLA
Christine C. Yang, et al.. "Tofacitinib for the treatment of lichen planopilaris: A case series.." Dermatologic therapy, vol. 31, no. 6, 2018, pp. e12656.
PMID
30264512 ↗
Abstract 한글 요약
Lichen planopilaris (LPP) is an inflammatory cicatricial alopecia for which many different therapies are attempted with varying success. The Janus kinase (JAK) inhibitor, tofacitinib, has been shown to be effective in treating the noncicatricial alopecia, alopecia areata. As in alopecia areata, upregulation of interferon and JAK signaling may play a role in LPP. We retrospectively reviewed the cases of 10 patients with recalcitrant LPP who were treated with oral tofacitinib. Patients received oral tofacitinib 5 mg twice or three times daily for 2-19 months as either monotherapy or adjunctive therapy to other ongoing treatments including intralesional triamcinolone, hydroxychloroquine, and tacrolimus ointment. Eight patients had clinical improvement in LPP with tofacitinib as either monotherapy (4/10) or adjunctive therapy (4/10). LPP Activity Index (LPPAI) before and after treatment was measured in seven patients and was significantly different (6.22 before treatment, 3.08 after treatment; p value = .0014). Reduction in LPPAI ranged from 30 to 94%. One patient complained of 10 pound (4.5 kg) weight gain after 12 months on tofacitinib. No other adverse effects were reported. Treatment with oral tofacitinib either as monotherapy or adjunctive therapy can lead to measurable improvement in recalcitrant LPP.
추출된 의학 개체 (NER)
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 질환 | alopecia areata
|
원형 탈모증 | dict | 2 | |
| 질환 | alopecia areata
|
원형 탈모증 | dict | 2 | |
| 질환 | alopecia areata
|
원형 탈모증 | dict | 2 |
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Administration
- Oral
- Adult
- Aged
- Alopecia
- Dermatologic Agents
- Drug Administration Schedule
- Female
- Humans
- Janus Kinase Inhibitors
- Lichen Planus
- Male
- Middle Aged
- Piperidines
- Pyrimidines
- Pyrroles
- Remission Induction
- Retrospective Studies
- Scalp
- Scalp Dermatoses
- Skin
- Time Factors
- Treatment Outcome
- JAK inhibitors
… 외 5개
인용 관계
그래프 OA 노드: 8/8 (100%)
· 참조 0편 · 후속 8편
이 논문을 인용한 후속 연구 14
- Frontal Fibrosing Alopecia: A Review.
- Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic …
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Dis…
- Primary cicatricial alopecias are characterized by dysregulation of shared gene expression pathways.
- JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia.
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series an…
- mTOR signaling in hair follicle and hair diseases: recent progress.
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopeci…
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative rev…
- The Frontal Fibrosing Alopecia Treatment Dilemma.
- Off-Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Pers…
- Frontal Fibrosing Alopecia: A Comprehensive Review with Recent Updates.
- Unveiling a Shared Precursor Condition for Acne Keloidalis Nuchae and Primary Cicatricial Alopecias.
- Photodistributed Lichenoid Eruption with Alopecia: A Unique Presentation of Graham-Little-Piccardi-L…
같은 제1저자의 인용 많은 논문 (5)
- Predictive Factors for the Successful Outcome of Urethral Sphincter Injections of Botulinum Toxin A for Non-Neurogenic Dysfunctional Voiding in Women.
- Higher plasma leptin is associated with higher risk of androgenetic alopecia in men.
- Early intervention with high-dose steroid pulse therapy prolongs disease-free interval of severe alopecia areata: a retrospective study.
- Calvitron automated hair transplant system in alopecia treatment: a case report.
- Empagliflozin protected kidney function in CKD rat through suppressing hypoxic and fibrotic signalings mediated inflammation and EMT.
📖 전문 본문 읽기 PMC JATS · ~22 KB · 영문 · 색칠된 단어 1개
INTRODUCTION
1
INTRODUCTION
Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia of unclear etiology. Although several treatments are available, they are often unsuccessful. Treatment with Janus kinase (JAK) inhibitors has been shown to be effective for the noncicatricial inflammatory alopecia, alopecia areata (Kennedy et al., 2016; Liu, Craiglow, Dai, & King, 2017; Mackay‐Wiggan et al., 2016). We report a case series of 10 adult patients with LPP who were treated with the pan‐JAK inhibitor, tofacitinib.
INTRODUCTION
Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia of unclear etiology. Although several treatments are available, they are often unsuccessful. Treatment with Janus kinase (JAK) inhibitors has been shown to be effective for the noncicatricial inflammatory alopecia, alopecia areata (Kennedy et al., 2016; Liu, Craiglow, Dai, & King, 2017; Mackay‐Wiggan et al., 2016). We report a case series of 10 adult patients with LPP who were treated with the pan‐JAK inhibitor, tofacitinib.
METHODS
2
METHODS
We reviewed the records of 10 adult patients who were treated with oral tofacitinib for LPP between October 2015 and May 2017. This study was approved by the Institutional Review Board of Columbia University. Clinical and demographic information for each patient was recorded, including age, sex, disease duration, biopsy results, prior treatments, tofacitinib dose, duration of tofacitinib treatment, and LPP Activity Index (LPPAI) (Chiang, Sah, Cho, Ochoa, & Price, 2010) when available. LPPAI is a numerical score that incorporates patient‐reported symptoms including pruritus, pain, and burning, as well as physical exam findings including erythema, perifollicular erythema, perifollicular scale, and evidence of disease activity via hair pull test positivity, and disease spreading (Chiang et al., 2010). Although this is not a validated scoring system, it facilitates statistical comparison. All patients were evaluated for complete blood count (CBC), comprehensive metabolic panel (CMP, including sodium, potassium, carbon dioxide, chloride, blood urea nitrogen, creatinine, glucose, albumin, total protein, and hepatic functional panel), and lipid panel prior to initiating treatment, at 4–8 weeks, and periodically thereafter.
METHODS
We reviewed the records of 10 adult patients who were treated with oral tofacitinib for LPP between October 2015 and May 2017. This study was approved by the Institutional Review Board of Columbia University. Clinical and demographic information for each patient was recorded, including age, sex, disease duration, biopsy results, prior treatments, tofacitinib dose, duration of tofacitinib treatment, and LPP Activity Index (LPPAI) (Chiang, Sah, Cho, Ochoa, & Price, 2010) when available. LPPAI is a numerical score that incorporates patient‐reported symptoms including pruritus, pain, and burning, as well as physical exam findings including erythema, perifollicular erythema, perifollicular scale, and evidence of disease activity via hair pull test positivity, and disease spreading (Chiang et al., 2010). Although this is not a validated scoring system, it facilitates statistical comparison. All patients were evaluated for complete blood count (CBC), comprehensive metabolic panel (CMP, including sodium, potassium, carbon dioxide, chloride, blood urea nitrogen, creatinine, glucose, albumin, total protein, and hepatic functional panel), and lipid panel prior to initiating treatment, at 4–8 weeks, and periodically thereafter.
RESULTS
3
RESULTS
Patient characteristics are detailed in Table 1. There were six females and four males and the average age at presentation was 55 years (range 33–68 years). The diagnosis of LPP was biopsy proven in five patients and was a clinical diagnosis in the remaining five patients. Patients 4 and 7 had scalp biopsies that were nondiagnostic, and they were determined clinically to be consistent with LPP. Prior attempted therapies included topical steroids (seven patients), intralesional triamcinolone (five patients), topical minoxidil (two patients), excimer laser (three patients), doxycycline (six patients), hydroxychloroquine (five patients), pioglitazone (four patients), finasteride (five patients), and mycophenolic acid (two patients). In all cases, there was inadequate control of disease; therefore, treatment with tofacitinib was pursued.
Treatment with tofacitinib ranged from 2 to 19 months and was dosed 5 mg twice a day for eight patients. Patients 1 and 7 continued to have the progression of disease while on tofacitinib 5 mg twice a day for 2 and 4 months, respectively, and their doses were increased to 5 mg three times a day. Tofacitinib was used as monotherapy in five patients. Adjunctive therapies were used in five patients and included intralesional triamcinolone (two patients), hydroxychloroquine (one patient), intralesional triamcinolone and hydroxychloroquine (one patient), and intralesional triamcinolone and tacrolimus ointment (one patient).
In eight patients, disease severity was assessed using the LPPAI, which incorporates objective and subjective markers of disease into a numeric score. The pre‐treatment LPPAI and post‐treatment LPPAI scores were compared using a paired t‐test, which showed a significant improvement in LPPAI score (p value = .0014). LPPAI improvement ranged from 30 to 94%. The change in LPPAI was not significantly different between patients who were on tofacitinib as monotherapy and those who had combination therapy (p = .2). LPPAI was not calculated for Patient 7; however, she was noted to have regrowth after 6 months on tofacitinib 5 mg three times daily. Thus, there was clinical response in 8 of the 10 patients. Improvement in erythema, scaling, and hair density is shown for Patients 4 and 9 in Figure 1. Two patients did not improve on tofacitinib and included Patient 3 who was on 5 mg twice daily for 3 months and stopped due to his concern about a report of bladder cancer associated with tofacitinib and Patient 6 who has been on 5 mg twice daily for 7 months; her dose was unable to be increased due to the lack of insurance coverage. After 12 months on tofacitinib, Patient 7 noted a weight gain of 10 pounds prompting her to discontinue therapy. After discontinuation, she experienced new hair loss and was restarted on tofacitinib 5 mg twice daily with subsequent stabilization of hair loss. There were no significant changes in CBC, CMP, or lipid panel in any patients. No other adverse effects were reported.
RESULTS
Patient characteristics are detailed in Table 1. There were six females and four males and the average age at presentation was 55 years (range 33–68 years). The diagnosis of LPP was biopsy proven in five patients and was a clinical diagnosis in the remaining five patients. Patients 4 and 7 had scalp biopsies that were nondiagnostic, and they were determined clinically to be consistent with LPP. Prior attempted therapies included topical steroids (seven patients), intralesional triamcinolone (five patients), topical minoxidil (two patients), excimer laser (three patients), doxycycline (six patients), hydroxychloroquine (five patients), pioglitazone (four patients), finasteride (five patients), and mycophenolic acid (two patients). In all cases, there was inadequate control of disease; therefore, treatment with tofacitinib was pursued.
Treatment with tofacitinib ranged from 2 to 19 months and was dosed 5 mg twice a day for eight patients. Patients 1 and 7 continued to have the progression of disease while on tofacitinib 5 mg twice a day for 2 and 4 months, respectively, and their doses were increased to 5 mg three times a day. Tofacitinib was used as monotherapy in five patients. Adjunctive therapies were used in five patients and included intralesional triamcinolone (two patients), hydroxychloroquine (one patient), intralesional triamcinolone and hydroxychloroquine (one patient), and intralesional triamcinolone and tacrolimus ointment (one patient).
In eight patients, disease severity was assessed using the LPPAI, which incorporates objective and subjective markers of disease into a numeric score. The pre‐treatment LPPAI and post‐treatment LPPAI scores were compared using a paired t‐test, which showed a significant improvement in LPPAI score (p value = .0014). LPPAI improvement ranged from 30 to 94%. The change in LPPAI was not significantly different between patients who were on tofacitinib as monotherapy and those who had combination therapy (p = .2). LPPAI was not calculated for Patient 7; however, she was noted to have regrowth after 6 months on tofacitinib 5 mg three times daily. Thus, there was clinical response in 8 of the 10 patients. Improvement in erythema, scaling, and hair density is shown for Patients 4 and 9 in Figure 1. Two patients did not improve on tofacitinib and included Patient 3 who was on 5 mg twice daily for 3 months and stopped due to his concern about a report of bladder cancer associated with tofacitinib and Patient 6 who has been on 5 mg twice daily for 7 months; her dose was unable to be increased due to the lack of insurance coverage. After 12 months on tofacitinib, Patient 7 noted a weight gain of 10 pounds prompting her to discontinue therapy. After discontinuation, she experienced new hair loss and was restarted on tofacitinib 5 mg twice daily with subsequent stabilization of hair loss. There were no significant changes in CBC, CMP, or lipid panel in any patients. No other adverse effects were reported.
DISCUSSION
4
DISCUSSION
In this report, we demonstrate that treatment with the pan‐JAK inhibitor, tofacitinib, resulted in clinically a measurable improvement in LPP in 80% of patients, either as monotherapy or as adjunctive therapy. Tofacitinib was well tolerated by all patients. There were two patients who did not improve on the 10 mg daily dose and, then, did respond after the dose was increased to 15 mg; therefore, it is possible that the two patients who did not show any improvement require a higher dose. Although this study is limited by its retrospective nature, small sample size, and heterogeneous patient group, improvements were seen in patients using tofacitinib monotherapy and with other concomitant treatment suggesting that JAK inhibition with tofacitinib may be a promising strategy for treating LPP, which often requires a multipronged approach for therapy.
LPP is considered a follicular variant of lichen planus and presents with alopecic patches, perifollicular erythema, scale, pruritus, burning, or tenderness. The etiology of LPP is unclear, and hypotheses include an autoimmune mechanism, collapse of hair follicle bulge immune privilege and bulge stem cell destruction, decreased peroxisome proliferator‐activated receptor‐ϒ signaling, and others (Rongioletti & Christana, 2012). Numerous therapies have been used including topical, intralesional, and systemic corticosteroids, hydroxychloroquine, immunosuppressants such as cyclosporine and mycophenolate mofetil, doxycycline, excimer laser, minoxidil, griseofulvin, oral retinoids, and thalidomide; response rates vary, and relapse is common (Rácz et al., 2013).
Tofacitinib is a pan‐JAK inhibitor approved by the FDA for the treatment of moderate‐to‐severe rheumatoid arthritis. It has recently been shown in clinical trials to be effective for psoriasis (Mamolo, Harness, Tan, & Menter, 2014; Papp et al., 2012) and vitiligo (Craiglow & King, 2015). Our group and others have established the clinical utility of JAK inhibitors in alopecia areata, a T‐cell mediated autoimmune nonscarring alopecia characterized by increased interferon (IFN)‐γ signaling (Kennedy et al., 2016; Liu et al., 2017; Mackay‐Wiggan et al., 2016). In a mouse model of alopecia areata, JAK inhibition led to the normalization of IFN‐pathway gene expression, decreased T‐cell infiltration, and hair regrowth (Xing et al., 2014).
A recent study has demonstrated a similar key role of IFN signaling in LPP (Harries et al., 2013). Expression of IFN‐inducible chemokines is increased in the hair follicle bulge and may be important in recruiting cytotoxic CD8+ cells. There is also evidence of bulge epithelial cell immune privilege collapse in LPP, as demonstrated by increased expression of major histocompatibility complex (MHC) class I and II and decreased expression of transforming growth factor (TGF) β and cluster of differentiation (CD) 200. In skin organ culture, IFNγ was shown to induce hair follicle immune privilege collapse, raising the possibility of blocking IFN signaling and restoring immune privilege as a therapeutic approach in LPP (Harries et al., 2013). A recent study examining JAK expression in the skin of patients with various inflammatory skin conditions showed that JAK1 and JAK3 are significantly upregulated in dermal inflammatory cells of a subset of patients with lichen planus, including LPP (Medeiros et al., 2016). Therefore, JAK inhibition may reduce IFN‐mediated inflammation associated with LPP and prevent further hair follicle destruction; this mechanism may account for the improvement observed in our patients. The promising findings in our case series invite further clinical investigation of JAK inhibitors in LPP in the setting of randomized, placebo‐controlled clinical trials in the future.
DISCUSSION
In this report, we demonstrate that treatment with the pan‐JAK inhibitor, tofacitinib, resulted in clinically a measurable improvement in LPP in 80% of patients, either as monotherapy or as adjunctive therapy. Tofacitinib was well tolerated by all patients. There were two patients who did not improve on the 10 mg daily dose and, then, did respond after the dose was increased to 15 mg; therefore, it is possible that the two patients who did not show any improvement require a higher dose. Although this study is limited by its retrospective nature, small sample size, and heterogeneous patient group, improvements were seen in patients using tofacitinib monotherapy and with other concomitant treatment suggesting that JAK inhibition with tofacitinib may be a promising strategy for treating LPP, which often requires a multipronged approach for therapy.
LPP is considered a follicular variant of lichen planus and presents with alopecic patches, perifollicular erythema, scale, pruritus, burning, or tenderness. The etiology of LPP is unclear, and hypotheses include an autoimmune mechanism, collapse of hair follicle bulge immune privilege and bulge stem cell destruction, decreased peroxisome proliferator‐activated receptor‐ϒ signaling, and others (Rongioletti & Christana, 2012). Numerous therapies have been used including topical, intralesional, and systemic corticosteroids, hydroxychloroquine, immunosuppressants such as cyclosporine and mycophenolate mofetil, doxycycline, excimer laser, minoxidil, griseofulvin, oral retinoids, and thalidomide; response rates vary, and relapse is common (Rácz et al., 2013).
Tofacitinib is a pan‐JAK inhibitor approved by the FDA for the treatment of moderate‐to‐severe rheumatoid arthritis. It has recently been shown in clinical trials to be effective for psoriasis (Mamolo, Harness, Tan, & Menter, 2014; Papp et al., 2012) and vitiligo (Craiglow & King, 2015). Our group and others have established the clinical utility of JAK inhibitors in alopecia areata, a T‐cell mediated autoimmune nonscarring alopecia characterized by increased interferon (IFN)‐γ signaling (Kennedy et al., 2016; Liu et al., 2017; Mackay‐Wiggan et al., 2016). In a mouse model of alopecia areata, JAK inhibition led to the normalization of IFN‐pathway gene expression, decreased T‐cell infiltration, and hair regrowth (Xing et al., 2014).
A recent study has demonstrated a similar key role of IFN signaling in LPP (Harries et al., 2013). Expression of IFN‐inducible chemokines is increased in the hair follicle bulge and may be important in recruiting cytotoxic CD8+ cells. There is also evidence of bulge epithelial cell immune privilege collapse in LPP, as demonstrated by increased expression of major histocompatibility complex (MHC) class I and II and decreased expression of transforming growth factor (TGF) β and cluster of differentiation (CD) 200. In skin organ culture, IFNγ was shown to induce hair follicle immune privilege collapse, raising the possibility of blocking IFN signaling and restoring immune privilege as a therapeutic approach in LPP (Harries et al., 2013). A recent study examining JAK expression in the skin of patients with various inflammatory skin conditions showed that JAK1 and JAK3 are significantly upregulated in dermal inflammatory cells of a subset of patients with lichen planus, including LPP (Medeiros et al., 2016). Therefore, JAK inhibition may reduce IFN‐mediated inflammation associated with LPP and prevent further hair follicle destruction; this mechanism may account for the improvement observed in our patients. The promising findings in our case series invite further clinical investigation of JAK inhibitors in LPP in the setting of randomized, placebo‐controlled clinical trials in the future.
CONFLICTS OF INTEREST
CONFLICTS OF INTEREST
Columbia University has filed patents on Dr. Christiano's research on the use of JAK inhibitors in the treatment of hair loss disorders, which have been licensed to Aclaris Therapeutics, Inc. Dr. Yang, Dr. Sallee, Dr. Bordone, and Ms. Khanna have no conflicts of interest.
Columbia University has filed patents on Dr. Christiano's research on the use of JAK inhibitors in the treatment of hair loss disorders, which have been licensed to Aclaris Therapeutics, Inc. Dr. Yang, Dr. Sallee, Dr. Bordone, and Ms. Khanna have no conflicts of interest.
출처: PubMed Central (JATS). 라이선스는 원 publisher 정책을 따릅니다 — 인용 시 원문을 표기해 주세요.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
📖 비슷한 OA 논문 — 같은 카테고리, 무료 전문 가능
-
Alopecia areata.
TL;DRAlopecia areata is difficult to manage medically, but recent advances in understanding the molecular mechanisms have revealed new treatments and the possibility of remission in the…
-
Epidemiology and burden of alopecia areata: a systematic review.
TL;DRAA is the most prevalent autoimmune disorder and the second most prevalent hair loss disorder after androgenetic alopecia, and the lifetime risk in the global population is approxi…
-
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
TL;DRIn two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks.
-
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
TL;DRAlthough a variety of medical, surgical, light‐based and nutraceutical treatment options are available to slow or reverse the progression of AGA, it can be challenging to select ap…
-
Hair follicle immune privilege and its collapse in alopecia areata.
TL;DRA key goal for effective AA management is the re‐establishment of a functional HF IP, which will also provide superior protection from disease relapse, and may confer increased sus…